CATALYST PHARMACEUTICALS INC (CPRX) Fundamental Analysis & Valuation
NASDAQ:CPRX • US14888U1016
Current stock price
23.33 USD
+0.03 (+0.13%)
At close:
23.4303 USD
+0.1 (+0.43%)
After Hours:
This CPRX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. CPRX Profitability Analysis
1.1 Basic Checks
- CPRX had positive earnings in the past year.
- In the past year CPRX had a positive cash flow from operations.
- CPRX had positive earnings in each of the past 5 years.
- CPRX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- With an excellent Return On Assets value of 19.41%, CPRX belongs to the best of the industry, outperforming 96.72% of the companies in the same industry.
- CPRX has a better Return On Equity (22.46%) than 96.14% of its industry peers.
- CPRX has a better Return On Invested Capital (20.39%) than 97.88% of its industry peers.
- CPRX had an Average Return On Invested Capital over the past 3 years of 19.09%. This is in line with the industry average of 19.43%.
- The last Return On Invested Capital (20.39%) for CPRX is above the 3 year average (19.09%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.41% | ||
| ROE | 22.46% | ||
| ROIC | 20.39% |
ROA(3y)17.95%
ROA(5y)18.52%
ROE(3y)21.13%
ROE(5y)22.03%
ROIC(3y)19.09%
ROIC(5y)20.07%
1.3 Margins
- Looking at the Profit Margin, with a value of 36.39%, CPRX belongs to the top of the industry, outperforming 97.10% of the companies in the same industry.
- CPRX's Profit Margin has declined in the last couple of years.
- CPRX's Operating Margin of 43.77% is amongst the best of the industry. CPRX outperforms 99.23% of its industry peers.
- In the last couple of years the Operating Margin of CPRX has grown nicely.
- CPRX's Gross Margin of 85.19% is amongst the best of the industry. CPRX outperforms 87.84% of its industry peers.
- CPRX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 43.77% | ||
| PM (TTM) | 36.39% | ||
| GM | 85.19% |
OM growth 3Y-2.71%
OM growth 5Y4.77%
PM growth 3Y-2.11%
PM growth 5Y-10.39%
GM growth 3Y0.49%
GM growth 5Y-0.11%
2. CPRX Health Analysis
2.1 Basic Checks
- CPRX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- CPRX has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for CPRX has been increased compared to 5 years ago.
- There is no outstanding debt for CPRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- CPRX has an Altman-Z score of 14.12. This indicates that CPRX is financially healthy and has little risk of bankruptcy at the moment.
- CPRX's Altman-Z score of 14.12 is amongst the best of the industry. CPRX outperforms 85.91% of its industry peers.
- CPRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 14.12 |
ROIC/WACC2.3
WACC8.87%
2.3 Liquidity
- A Current Ratio of 6.08 indicates that CPRX has no problem at all paying its short term obligations.
- With a decent Current ratio value of 6.08, CPRX is doing good in the industry, outperforming 63.32% of the companies in the same industry.
- A Quick Ratio of 5.82 indicates that CPRX has no problem at all paying its short term obligations.
- CPRX has a better Quick ratio (5.82) than 62.93% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.08 | ||
| Quick Ratio | 5.82 |
3. CPRX Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 29.01% over the past year.
- The Earnings Per Share has been growing by 32.75% on average over the past years. This is a very strong growth
- Looking at the last year, CPRX shows a quite strong growth in Revenue. The Revenue has grown by 19.78% in the last year.
- Measured over the past years, CPRX shows a very strong growth in Revenue. The Revenue has been growing by 37.67% on average per year.
EPS 1Y (TTM)29.01%
EPS 3Y31.69%
EPS 5Y32.75%
EPS Q2Q%-6.82%
Revenue 1Y (TTM)19.78%
Revenue growth 3Y40.1%
Revenue growth 5Y37.67%
Sales Q2Q%7.61%
3.2 Future
- CPRX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.46% yearly.
- The Revenue is expected to grow by 9.11% on average over the next years. This is quite good.
EPS Next Y14.31%
EPS Next 2Y13.06%
EPS Next 3Y6.95%
EPS Next 5Y25.46%
Revenue Next Year7.82%
Revenue Next 2Y8.79%
Revenue Next 3Y8.45%
Revenue Next 5Y9.11%
3.3 Evolution
- Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. CPRX Valuation Analysis
4.1 Price/Earnings Ratio
- CPRX is valuated correctly with a Price/Earnings ratio of 13.80.
- Compared to the rest of the industry, the Price/Earnings ratio of CPRX indicates a rather cheap valuation: CPRX is cheaper than 95.95% of the companies listed in the same industry.
- CPRX's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.11.
- The Price/Forward Earnings ratio is 12.08, which indicates a correct valuation of CPRX.
- 97.30% of the companies in the same industry are more expensive than CPRX, based on the Price/Forward Earnings ratio.
- CPRX is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 24.12, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.8 | ||
| Fwd PE | 12.08 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CPRX indicates a rather cheap valuation: CPRX is cheaper than 97.88% of the companies listed in the same industry.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of CPRX indicates a rather cheap valuation: CPRX is cheaper than 97.30% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.66 | ||
| EV/EBITDA | 7.23 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The excellent profitability rating of CPRX may justify a higher PE ratio.
PEG (NY)0.96
PEG (5Y)0.42
EPS Next 2Y13.06%
EPS Next 3Y6.95%
5. CPRX Dividend Analysis
5.1 Amount
- No dividends for CPRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
CPRX Fundamentals: All Metrics, Ratios and Statistics
23.33
+0.03 (+0.13%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25 2026-02-25/amc
Earnings (Next)05-05 2026-05-05
Inst Owners88.61%
Inst Owner Change-0.37%
Ins Owners5.59%
Ins Owner Change0.25%
Market Cap2.85B
Revenue(TTM)588.99M
Net Income(TTM)214.33M
Analysts88.57
Price Target35.19 (50.84%)
Short Float %8.13%
Short Ratio7.42
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.83%
Min EPS beat(2)19.63%
Max EPS beat(2)24.03%
EPS beat(4)4
Avg EPS beat(4)19.39%
Min EPS beat(4)4.13%
Max EPS beat(4)29.76%
EPS beat(8)7
Avg EPS beat(8)17.18%
EPS beat(12)10
Avg EPS beat(12)14.79%
EPS beat(16)13
Avg EPS beat(16)11.51%
Revenue beat(2)2
Avg Revenue beat(2)5.84%
Min Revenue beat(2)5.34%
Max Revenue beat(2)6.34%
Revenue beat(4)4
Avg Revenue beat(4)4.83%
Min Revenue beat(4)2.19%
Max Revenue beat(4)6.34%
Revenue beat(8)7
Avg Revenue beat(8)3.89%
Revenue beat(12)11
Avg Revenue beat(12)3.56%
Revenue beat(16)14
Avg Revenue beat(16)3.41%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)2.27%
EPS NQ rev (3m)-26.23%
EPS NY rev (1m)6.4%
EPS NY rev (3m)-4.82%
Revenue NQ rev (1m)2.96%
Revenue NQ rev (3m)3.29%
Revenue NY rev (1m)0.81%
Revenue NY rev (3m)0.67%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.8 | ||
| Fwd PE | 12.08 | ||
| P/S | 4.84 | ||
| P/FCF | 13.66 | ||
| P/OCF | 13.65 | ||
| P/B | 2.99 | ||
| P/tB | 3.46 | ||
| EV/EBITDA | 7.23 |
EPS(TTM)1.69
EY7.24%
EPS(NY)1.93
Fwd EY8.28%
FCF(TTM)1.71
FCFY7.32%
OCF(TTM)1.71
OCFY7.32%
SpS4.82
BVpS7.81
TBVpS6.74
PEG (NY)0.96
PEG (5Y)0.42
Graham Number17.24
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.41% | ||
| ROE | 22.46% | ||
| ROCE | 26.94% | ||
| ROIC | 20.39% | ||
| ROICexc | 78.78% | ||
| ROICexgc | 168.22% | ||
| OM | 43.77% | ||
| PM (TTM) | 36.39% | ||
| GM | 85.19% | ||
| FCFM | 35.42% |
ROA(3y)17.95%
ROA(5y)18.52%
ROE(3y)21.13%
ROE(5y)22.03%
ROIC(3y)19.09%
ROIC(5y)20.07%
ROICexc(3y)57.9%
ROICexc(5y)154.04%
ROICexgc(3y)178.31%
ROICexgc(5y)N/A
ROCE(3y)25.22%
ROCE(5y)26.51%
ROICexgc growth 3YN/A
ROICexgc growth 5Y9.61%
ROICexc growth 3Y-41.48%
ROICexc growth 5Y-5.82%
OM growth 3Y-2.71%
OM growth 5Y4.77%
PM growth 3Y-2.11%
PM growth 5Y-10.39%
GM growth 3Y0.49%
GM growth 5Y-0.11%
F-Score6
Asset Turnover0.53
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 0.15% | ||
| Cap/Sales | 0.01% | ||
| Interest Coverage | 553.17 | ||
| Cash Conversion | 70.58% | ||
| Profit Quality | 97.33% | ||
| Current Ratio | 6.08 | ||
| Quick Ratio | 5.82 | ||
| Altman-Z | 14.12 |
F-Score6
WACC8.87%
ROIC/WACC2.3
Cap/Depr(3y)0.78%
Cap/Depr(5y)100.47%
Cap/Sales(3y)0.06%
Cap/Sales(5y)0.18%
Profit Quality(3y)148.03%
Profit Quality(5y)146.81%
High Growth Momentum
Growth
EPS 1Y (TTM)29.01%
EPS 3Y31.69%
EPS 5Y32.75%
EPS Q2Q%-6.82%
EPS Next Y14.31%
EPS Next 2Y13.06%
EPS Next 3Y6.95%
EPS Next 5Y25.46%
Revenue 1Y (TTM)19.78%
Revenue growth 3Y40.1%
Revenue growth 5Y37.67%
Sales Q2Q%7.61%
Revenue Next Year7.82%
Revenue Next 2Y8.79%
Revenue Next 3Y8.45%
Revenue Next 5Y9.11%
EBIT growth 1Y32.11%
EBIT growth 3Y36.3%
EBIT growth 5Y44.23%
EBIT Next Year28.53%
EBIT Next 3Y17.44%
EBIT Next 5YN/A
FCF growth 1Y-12.81%
FCF growth 3Y21.61%
FCF growth 5Y35.9%
OCF growth 1Y-12.98%
OCF growth 3Y21.62%
OCF growth 5Y35.91%
CATALYST PHARMACEUTICALS INC / CPRX Fundamental Analysis FAQ
What is the ChartMill fundamental rating of CATALYST PHARMACEUTICALS INC (CPRX) stock?
ChartMill assigns a fundamental rating of 7 / 10 to CPRX.
What is the valuation status for CPRX stock?
ChartMill assigns a valuation rating of 7 / 10 to CATALYST PHARMACEUTICALS INC (CPRX). This can be considered as Undervalued.
Can you provide the profitability details for CATALYST PHARMACEUTICALS INC?
CATALYST PHARMACEUTICALS INC (CPRX) has a profitability rating of 8 / 10.
What is the expected EPS growth for CATALYST PHARMACEUTICALS INC (CPRX) stock?
The Earnings per Share (EPS) of CATALYST PHARMACEUTICALS INC (CPRX) is expected to grow by 14.31% in the next year.